Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 6Carcinoma, Renal Cell 4Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroendocrine Tumors 1Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Kidney Neoplasms 1

Interventions

Dacarbazine 4pembrolizumab 3binimetinib 3Nivolumab 3encorafenib 2cemiplimab 2Sirolimus 2Ipilimumab 2vitespin 1trametinib 1tilsotolimod 1spartalizumab 1oblimersen 1linrodostat 1lifileucel 1gp100 Melanoma Antigen 1dabrafenib 1bempegaldesleukin 1aldesleukin 1Vinblastine 1Vemurafenib 1Tretinoin 1Tacrolimus 1Standard of Care 1Sodium Chloride 1Radiotherapy 1Radiation 1Interleukin-2 1Interferon-alpha 1Interferon alpha-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Skin Neoplasms × Interferon alpha-2 × Clear all
NCT00002882 2011-12-13

Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma

M.D. Anderson Cancer Center

Phase 3 Completed
140 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡